抗HIV抗体药物研究进展  

Research progress of anti-HIV antibody drugs

作　　者：陈莹(综述) 潘勇兵(审校) Chen Ying;Pan Yongbing(Antibody Laboratory,Wuhan Institute of Biological Products Co.,Ltd.,Wuhan 430207,China)

机构地区：[1]武汉生物制品研究所有限责任公司抗体研究室,430207

出　　处：《国际生物制品学杂志》2019年第6期284-288,共5页International Journal of Biologicals

摘　　要：HIV-1感染是危害全球公共健康的严重问题。随着抗体技术的不断进步,一些抗HIV单克隆抗体在临床试验中取得了较好的结果,第一个用于治疗HIV感染的单克隆抗体药物Ibalizumab已上市。针对HIV的双特异性和多特异性抗体的研发也取得了较大进展,但同时也面临挑战。HIV-1 infection is a serious problem endangering global public health.With the continuous progress of antibody technology,many anti-HIV monoclonal antibodies have shown satisfying outcome in clinical trials,The first monoclonal antibody drug for HIV-infection treatment,Ibalizumab,has come onto market.In addition,the research and development of bi-specific and multi-specific antibodies against HIV has also made great progress,but also facing some challenges.

关 键 词：HIV 抗体 中和 治疗 临床研究性 

分 类 号：R51[医药卫生—内科学]